KRON

Kronos Bio Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website kronosbio.com
Employees(FY) 99
ISIN US50107A1043

Performance

-6.51%

-9.47%

-14.0%

-15.69%

-31.2%

YTD

-28.33%

Profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Advanced Technical Analysis

Technical Analysis of KRON 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend leans...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of KRON

Stock Rank

Recent News & Updates

2024-11-14 03:02
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024(Globenewswire)
2024-11-14 00:24
Kronos mulls strategic alternatives after axing cancer drug development(Yahoo Finance)
2024-11-13 04:30
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-11-13 03:05
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives(Globenewswire)
2024-11-04 20:00
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma(Globenewswire)
2024-10-22 20:55
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors(Globenewswire)
2024-10-08 20:55
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors(Globenewswire)
2024-10-06 20:55
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sj gren's Disease(Globenewswire)
2024-10-06 20:55
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjogren's Disease(Globenewswire)
2024-09-24 20:55
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy(Globenewswire)
2024-09-22 20:55
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer(Globenewswire)
2024-09-09 21:35
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)(Yahoo Finance)
2024-09-02 20:55
Kronos Bio Announces Participation in Medical and Investor Conferences in September(Globenewswire)
2024-08-21 21:35
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)(Yahoo Finance)
2024-08-08 04:15
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update(Yahoo Finance)
2024-08-05 22:00
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?(Yahoo Finance)
2024-07-23 04:15
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer(Globenewswire)
2024-05-23 05:15
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-05-22 04:30
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events(Globenewswire)
2024-05-20 20:15
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer(Globenewswire)
2024-05-15 21:35
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround(Zacks)
2024-05-09 10:55
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-09 05:45
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-09 04:05
Kronos Bio Reports First-Quarter 2024 Financial Results(Globenewswire)
2024-04-24 04:01
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-03-27 00:00
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?(Zacks)
2024-03-21 01:53
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023(Investorplace)
2024-03-20 19:05
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results(Globenewswire)
2024-03-07 03:05
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway(Globenewswire)
2024-03-05 03:44
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.